Palonosetron.txt

CLINICAL USE

Anti-emetic:For use with cancer chemotherapy

DOSE IN NORMAL RENAL FUNCTION

250 mcg as a single dose approximately 30 minutes before chemotherapy

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :332.9 (as hydrochloride)

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :62

%Excreted unchanged in urine &nbsp &nbsp : 40

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :6.9–7.9

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :40

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 &nbsp &nbsp : Dose as in normal renal function

10 to 20 &nbsp &nbsp : Dose as in normal renal function

<10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in normal renal function

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unlikely to be dialysed. Dose as in normal renal function

HDF/high flux &nbsp :Unknown dialysability. Dose as in normal renal function

CAV/VVHD &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugsNone

ADMINISTRATION

Reconstition

–

Route

IV bolus

Rate of Administration

30 seconds

Comments

–

OTHER INFORMATION

Repeated doses within 7 days are not recommendedUse with caution in people at risk of QT prolongation.

Tags: post-by-auto-php